GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AUPH · Sep 30, 2022

Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-22-027931General Corporate

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-27.54% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

280.30% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

45.39% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

95.61% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-17.03% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

19.67% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

14.92% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesSelf-history eligible

Mar 31, 20210/6 normalizedLevel 3 Jun 30, 20210/6 normalizedLevel 3 Sep 30, 20210/6 normalizedLevel 3 Dec 31, 20210/7 normalizedLevel 3 Mar 31, 20220/7 normalizedLevel 3 Jun 30, 20220/7 normalizedLevel 3 Sep 30, 20220/7 normalizedLevel 3 Dec 31, 20225/7 normalizedLevel 3 Mar 31, 20236/7 normalizedLevel 3 Jun 30, 20236/7 normalizedLevel 3 Sep 30, 20236/7 normalizedLevel 3 Sep 30, 20267/7 normalizedLevel 4

Period transition

What moved in the state?

Cash Generation Increased

Previous: -98.86%
Current: -27.54%
Delta: 71.32%

Growth Decreased

Previous: 325.85%
Current: 280.30%
Delta: -45.54%

Inventory Pressure Decreased

Previous: 91.74%
Current: 45.39%
Delta: -46.35%

Margin Increased

Previous: 94.33%
Current: 95.61%
Delta: 1.29%

Profitability Increased

Previous: -127.66%
Current: -17.03%
Delta: 110.63%

R And D Intensity Decreased

Previous: 40.88%
Current: 19.67%
Delta: -21.21%

Sbc Intensity Decreased

Previous: 35.67%
Current: 14.92%
Delta: -20.75%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_INCREASED →Transitioned To · AUPH GROWTH_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_DECREASED →Transitioned To · AUPH MARGIN_INCREASED →Transitioned To · AUPH PROFITABILITY_INCREASED →Transitioned To · AUPH R_AND_D_INTENSITY_DECREASED →Transitioned To · AUPH SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.